Positive zinc intake and a Japanese diet rich in n-3 fatty acids induces clinical remission in patients with mild active ulcerative colitis: a randomized interventional pilot study
Abstract
Zinc intake has reduced hospitalizations in patients with ulcerative colitis (UC), highlighting the need to maintain blood zinc levels. This prospective study investigated whether the promotion of zinc intake and a Japanese diet (high in n-3 fatty acids) could induce clinical remission in patients with mild active UC. Patients with mild active UC were randomly assigned to either (1) continue an unrestricted diet or (2) receive nutritional guidance promoting zinc intake and a Japanese diet. The primary endpoint was clinical remission at 24 weeks. Secondary endpoints were the Ulcerative Colitis Endoscopic Index of Severity (UCEIS) scores, Clinical Activity Index (CAI), Geboes Histopathology Score (GHS), and biomarkers, including zinc levels, measured at 12 and 24 weeks. Nutritional assessments were performed using the Food Frequency Questionnaire. The CAI, UCEIS, and GHS scores were significantly lower in the intervention group than in the control group, with a significantly higher proportion of patients achieving clinical remission. Furthermore, the intervention group exhibited weight gain and significantly increased blood zinc levels. The combination of promoting dietary zinc intake and a Japanese diet rich in n-3 fatty acids can induce clinical remission in patients with mild active UC.
Miyaguchi, K., Tsuzuki, Y., Ichikawa, Y., Shiomi, R., Ohgo, H., Nakamoto, H., & Imaeda, H. (2022). Positive zinc intake and a Japanese diet rich in n-3 fatty acids induces clinical remission in patients with mild active ulcerative colitis: a randomized interventional pilot study. Journal of Clinical Biochemistry and Nutrition, 22–72. https://doi.org/10.3164/jcbn.22-72
Pilot data indicate that promotion of both zinc intake and a Japanese diet rich in n-3 fatty acids may help induce clinical remission in patients with mild active UC. Nonetheless, large-scale randomized controlled trials are required to validate our findings.
Support our Mission
Your donation will help us to enhance the well-being and health outcomes of patients with IBD.
Donate